Immunic, Inc. Announces 1-for-10 Reverse Stock Split: Key Investor Implications

Overview

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company focusing on novel oral therapies for neurologic diseases, has announced a 1-for-10 reverse stock split of its outstanding common shares. The split will become effective at 12:01 a.m. Eastern Time on April 27, 2026. IMUX shares will continue to trade on the Nasdaq Capital Market, but will begin trading on a split-adjusted basis from the opening of the market on that day, under the new CUSIP number 4525EP200.

Key Points from the Report

• Reverse Stock Split Details: Every ten shares of issued and outstanding common stock will be consolidated into one share. No fractional shares will be issued; instead, all fractional shares will be aggregated and sold on the open market, with cash payments made to shareholders in lieu of fractional shares.
• Share Count Impact: The reverse split will reduce the number of issued and outstanding shares from approximately 136 million to roughly 13.6 million.
• Shareholder Approval: The split was approved at a special meeting of stockholders on April 14, 2026, allowing the Board discretion to select a ratio between 1-for-10 and 1-for-30. The Board chose 1-for-10.
• Purpose of the Split: The reverse split is intended to help Immunic meet contractual obligations under a securities purchase agreement with institutional and accredited investors from February 12, 2026.
• Effect on Shareholder Ownership: The split will affect all stockholders uniformly and will not change any ownership percentages, except for those receiving cash in lieu of fractional shares.
• Adjustment of Securities: All outstanding stock options, warrants, restricted stock units, and similar securities will be proportionally adjusted to reflect the reverse split, both in terms of exercise prices and the number of underlying shares.
• No Change to Authorized Shares or Par Value: The number of authorized shares and the par value will remain unchanged.
• Further Information: Detailed information is available in the company’s definitive proxy statement filed with the SEC on March 2, 2026, accessible via Immunic’s Investor Relations page.

Potential Price-Sensitive Information for Shareholders

• Reverse Split May Affect Share Price: Reverse stock splits often impact share prices due to changes in share count and investor perceptions. While the split itself does not alter the company’s market capitalization, it can influence trading dynamics and liquidity.
• Contractual Obligations: The split is a requirement to meet obligations to investors from a recent securities purchase agreement, which may signal ongoing capital needs or strategic transactions.
• Adjustment of Dilutive Securities: Proportional adjustments to options, warrants, and other convertible securities may affect future dilution and shareholder value.
• Cash Payment for Fractional Shares: Shareholders holding amounts not evenly divisible by 10 will receive cash payments, potentially affecting small shareholders.
• Ongoing Clinical Progress: Immunic’s lead program, vidofludimus calcium (IMU-838), is in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026. The drug has shown therapeutic activity in earlier trials for multiple sclerosis and other diseases, providing a potential upside if results are positive.
• Risks and Forward-Looking Statements: The company highlights substantial risks, including macroeconomic trends, geopolitical conflicts, financial resources, ability to raise capital, and regulatory challenges. These factors could significantly affect future performance and share value.

Company Pipeline and Outlook

Immunic is developing vidofludimus calcium (IMU-838) as its lead program, targeting relapsing multiple sclerosis. The compound is a first-in-class Nurr1 activator, offering neuroprotective, anti-inflammatory, and anti-viral effects. Earlier-stage pipeline candidates include IMU-856 and IMU-381, targeting neurodegenerative, chronic inflammatory, and autoimmune-related diseases. The company expects pivotal trial data by year-end 2026, which could be a significant catalyst for share price movement.

Contact Information

• Jessica Breu, Vice President Investor Relations and Communications: +49 89 2080 477 09, [email protected]
• US IR Contact: Rx Communications Group, Paula Schwartz, +1 917 633 7790, [email protected]
• US Media Contact: KCSA Strategic Communications, Caitlin Kasunich, +1 212 896 1241, [email protected]

Investor Considerations

• The reverse stock split is a significant corporate action that may impact IMUX’s share price and trading liquidity.
• The company is actively developing a late-stage drug, with critical data expected soon, which could materially affect valuation and share price.
• Investors should monitor ongoing capital needs and risks highlighted by management, including cash utilization, regulatory hurdles, and macroeconomic factors.
• All outstanding dilutive securities will be adjusted, potentially affecting future dilution.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to substantial risks and uncertainties, and actual outcomes may differ materially from those projected. Investors are advised to review Immunic’s SEC filings, including risk factors, before making investment decisions. The author and publisher expressly disclaim any liability for actions taken based on this article.

View IMMUNIC, INC. Historical chart here